Quantity of suitable clients: CDEC reviewed the uncertainty in the amount of sufferers with reasonably intense to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific professionals consulted by CADTH indicated that some individuals who're categorized as acquiring gentle or reasonable disease could have a severe bleeding phenotype, which https://hemgenix38261.topbloghub.com/42386205/new-step-by-step-map-for-hemgenix